Sign in Sign up for free

Last updated: 19 July 2024 at 5:20pm EST

Karen Licitra Net Worth




The estimated Net Worth of Karen A Licitra is at least $434 Thousand dollars as of 25 June 2021. Ms. Licitra owns over 21,408 units of Angiodynamic Inc stock worth over $224,121 and over the last 5 years she sold ANGO stock worth over $0. In addition, she makes $210,130 as Independent Director at Angiodynamic Inc.

Ms. Licitra ANGO stock SEC Form 4 insiders trading

Karen has made over 1 trades of the Angiodynamic Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 21,408 units of ANGO stock worth $92,483 on 25 June 2021.

The largest trade she's ever made was exercising 21,408 units of Angiodynamic Inc stock on 25 June 2021 worth over $92,483. On average, Karen trades about 2,379 units every 0 days since 2019. As of 25 June 2021 she still owns at least 30,205 units of Angiodynamic Inc stock.

You can see the complete history of Ms. Licitra stock trades at the bottom of the page.





Karen Licitra biography

Karen A. Licitra serves as Independent Director of the Company. Ms. Licitra was appointed to fill a vacancy on our Board of Directors on July 17, 2019. From January 2014 through August 2015, Ms. Licitra served as Corporate Vice President, Worldwide Government Affairs & Policy at Johnson & Johnson, a medical devices, pharmaceutical, and consumer packaged goods manufacturer. From December 2011 to December 2013, Ms. Licitra served as the Worldwide Chairman, Global Medical Solutions at Johnson & Johnson. From July 2002 to November 2011, she served as the Company Group Chairman and Worldwide Franchise Chairman at Ethicon Endo-Surgery, Inc., a Johnson & Johnson medical device company. From January 2001 to June 2002, she served as the President of Ethicon Endo-Surgery. Ms. Licitra currently serves on the board of directors of Si-Bone, Inc., medical device company focusing on a minimally invasive surgical implant system to treat sacroiliac joint dysfunction, and previously served on the board of directors of Novadaq Technologies Inc., a provider of proven comprehensive fluorescence imaging solutions, until the company was acquired by Stryker Corporation in 2017. Ms. Licitra received a B.S. in Commerce from Rider College. Ms. Licitra is a member of our Compensation Committee.

What is the salary of Karen Licitra?

As the Independent Director of Angiodynamic Inc, the total compensation of Karen Licitra at Angiodynamic Inc is $210,130. There are 16 executives at Angiodynamic Inc getting paid more, with James Clemmer having the highest compensation of $3,116,630.



How old is Karen Licitra?

Karen Licitra is 60, she's been the Independent Director of Angiodynamic Inc since 2019. There are 2 older and 23 younger executives at Angiodynamic Inc. The oldest executive at Angiodynamic Inc is Dennis Meteny, 67, who is the Independent Director.

What's Karen Licitra's mailing address?

Karen's mailing address filed with the SEC is 14 PLAZA DRIVE, , LATHAM, NY, 12110.

Insiders trading at Angiodynamic Inc

Over the last 20 years, insiders at Angiodynamic Inc have traded over $207,843,757 worth of Angiodynamic Inc stock and bought 255,612 units worth $3,086,102 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman, and Capital Partners Gp, Llc Av.... On average, Angiodynamic Inc executives and independent directors trade stock every 36 days with the average trade being worth of $826,492. The most recent stock trade was executed by Laura Piccinini on 17 July 2024, trading 4,439 units of ANGO stock currently worth $32,937.



What does Angiodynamic Inc do?

founded in 1988 in queensbury, n.y., u.s., angiodynamics is today a nasdaq-listed public company. we are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. our diverse product line includes market-leading radiofrequency ablation and nanoknife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. angiodynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company’s consistent ability to successfully develop and bring to market new technologies and products. angiodynamics believes it is well poised to continue that trend. looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patie



What does Angiodynamic Inc's logo look like?

Angiodynamic Inc logo

Complete history of Ms. Licitra stock trades at Angiodynamic Inc and SI-BONE Inc

Date
#
Company
 Insider
Trans.
Transaction
 Shares Price per share Total value Shares after Source
25 Jun 2021 SIBN SI-BONE Inc Karen A Licitra
Option 21,408 $4.32 $92,483
25 Jun 2021
30,205 ↗


Angiodynamic Inc executives and stock owners

Angiodynamic Inc executives and other stock owners filed with the SEC include: